Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats

Toshitaka Nabeshima, Kazuhiro Ishikawa, Kazumasa Yamaguchi, Hiroshi Furukawa, Tsutomu Kameyama

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic phencyclidine (PCP) administration has been shown to produce tolerance to a number of its pharmacological actions. We have suggested that PCP interacts with the 5-HT2 receptors since it inhibits [3H]spiperone binding to 5-HT2 receptors in vitro. In the present study, we investigated whether methysergide (a 5-HT2 receptor blocker) induces the precipitated withdrawal syndrome in PCP-tolerant rats. The body weight of the rats in the abrupt and precipitated withdrawal groups was significantly lower 5 days and 1-5 days after withdrawal, respectively, than that in the control group. Furthermore, other typical precipitated abstinence syndrome characteristics such as jumping, wet-dog shake and ptosis were also observed in the precipitated withdrawal group. These results suggest that PCP produces its behavioral effects via an agonistic interaction with 5-HT2 receptor sites and that our method may be very useful for the development of a rat model for studying physical dependence on PCP.

Original languageEnglish
Pages (from-to)275-278
Number of pages4
JournalNeuroscience Letters
Volume69
Issue number3
DOIs
Publication statusPublished - 12-09-1986
Externally publishedYes

Fingerprint

Methysergide
Phencyclidine
Spiperone
Body Weight
Pharmacology
Dogs
Control Groups

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Nabeshima, Toshitaka ; Ishikawa, Kazuhiro ; Yamaguchi, Kazumasa ; Furukawa, Hiroshi ; Kameyama, Tsutomu. / Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats. In: Neuroscience Letters. 1986 ; Vol. 69, No. 3. pp. 275-278.
@article{30ea7366fbae4b079a77f449234a76c5,
title = "Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats",
abstract = "Chronic phencyclidine (PCP) administration has been shown to produce tolerance to a number of its pharmacological actions. We have suggested that PCP interacts with the 5-HT2 receptors since it inhibits [3H]spiperone binding to 5-HT2 receptors in vitro. In the present study, we investigated whether methysergide (a 5-HT2 receptor blocker) induces the precipitated withdrawal syndrome in PCP-tolerant rats. The body weight of the rats in the abrupt and precipitated withdrawal groups was significantly lower 5 days and 1-5 days after withdrawal, respectively, than that in the control group. Furthermore, other typical precipitated abstinence syndrome characteristics such as jumping, wet-dog shake and ptosis were also observed in the precipitated withdrawal group. These results suggest that PCP produces its behavioral effects via an agonistic interaction with 5-HT2 receptor sites and that our method may be very useful for the development of a rat model for studying physical dependence on PCP.",
author = "Toshitaka Nabeshima and Kazuhiro Ishikawa and Kazumasa Yamaguchi and Hiroshi Furukawa and Tsutomu Kameyama",
year = "1986",
month = "9",
day = "12",
doi = "10.1016/0304-3940(86)90493-3",
language = "English",
volume = "69",
pages = "275--278",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats. / Nabeshima, Toshitaka; Ishikawa, Kazuhiro; Yamaguchi, Kazumasa; Furukawa, Hiroshi; Kameyama, Tsutomu.

In: Neuroscience Letters, Vol. 69, No. 3, 12.09.1986, p. 275-278.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats

AU - Nabeshima, Toshitaka

AU - Ishikawa, Kazuhiro

AU - Yamaguchi, Kazumasa

AU - Furukawa, Hiroshi

AU - Kameyama, Tsutomu

PY - 1986/9/12

Y1 - 1986/9/12

N2 - Chronic phencyclidine (PCP) administration has been shown to produce tolerance to a number of its pharmacological actions. We have suggested that PCP interacts with the 5-HT2 receptors since it inhibits [3H]spiperone binding to 5-HT2 receptors in vitro. In the present study, we investigated whether methysergide (a 5-HT2 receptor blocker) induces the precipitated withdrawal syndrome in PCP-tolerant rats. The body weight of the rats in the abrupt and precipitated withdrawal groups was significantly lower 5 days and 1-5 days after withdrawal, respectively, than that in the control group. Furthermore, other typical precipitated abstinence syndrome characteristics such as jumping, wet-dog shake and ptosis were also observed in the precipitated withdrawal group. These results suggest that PCP produces its behavioral effects via an agonistic interaction with 5-HT2 receptor sites and that our method may be very useful for the development of a rat model for studying physical dependence on PCP.

AB - Chronic phencyclidine (PCP) administration has been shown to produce tolerance to a number of its pharmacological actions. We have suggested that PCP interacts with the 5-HT2 receptors since it inhibits [3H]spiperone binding to 5-HT2 receptors in vitro. In the present study, we investigated whether methysergide (a 5-HT2 receptor blocker) induces the precipitated withdrawal syndrome in PCP-tolerant rats. The body weight of the rats in the abrupt and precipitated withdrawal groups was significantly lower 5 days and 1-5 days after withdrawal, respectively, than that in the control group. Furthermore, other typical precipitated abstinence syndrome characteristics such as jumping, wet-dog shake and ptosis were also observed in the precipitated withdrawal group. These results suggest that PCP produces its behavioral effects via an agonistic interaction with 5-HT2 receptor sites and that our method may be very useful for the development of a rat model for studying physical dependence on PCP.

UR - http://www.scopus.com/inward/record.url?scp=0022922090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022922090&partnerID=8YFLogxK

U2 - 10.1016/0304-3940(86)90493-3

DO - 10.1016/0304-3940(86)90493-3

M3 - Article

VL - 69

SP - 275

EP - 278

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 3

ER -